MediWound (NASDAQ:MDWD) Shares Pass Below 200-Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.40 and traded as low as $16.05. MediWound shares last traded at $16.29, with a volume of 28,922 shares changing hands.

Wall Street Analyst Weigh In

MDWD has been the topic of several recent analyst reports. Craig Hallum started coverage on MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of MediWound in a research report on Thursday, March 20th. Finally, StockNews.com upgraded shares of MediWound to a “sell” rating in a report on Friday, March 21st.

MediWound Stock Performance

The business’s 50 day moving average price is $16.93 and its 200-day moving average price is $17.39. The company has a market cap of $184.82 million, a price-to-earnings ratio of -5.90 and a beta of 0.50.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company posted ($0.19) earnings per share. On average, equities research analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of MediWound

Large investors have recently made changes to their positions in the business. R Squared Ltd bought a new position in shares of MediWound in the 4th quarter valued at about $32,000. GAMMA Investing LLC raised its stake in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,703 shares during the period. Russell Investments Group Ltd. lifted its stake in MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,162 shares in the last quarter. Bank of America Corp DE boosted its holdings in MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,178 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.